

Novel triple-drug cocktail for glioblastoma exhibits potent synergistic antitumoral effects


Paulo Faria, Mansoor M. Amiji, Hélder A. Santos, Bruno Sarmento

PhD STUDENT
i3S INSTITUTE, UNIVERSITY OF PORTO, PORTUGAL

JULY 18TH 2025

The burden of Glioblastoma (GBM)

- Most **common** and **lethal** type of brain cancer
- **15 months median survival** and very high **recurrence** rate (~90%)



- Standard-of-care → Surgery + Radiotherapy + **Chemotherapy with Temozolomide (TMZ)**
- Chemoresistance and Blood-brain barrier (BBB) pose main challenges for treatment

Stupp et al., N. Engl. J. Med, 2005




MGMT

OUR SOLUTION

Triple drug cocktail in hydrogel to defeat GBM

- Eradicate tumor cells with **TMZ**
- Revert chemoresistance to **TMZ** with **O⁶-Benzylguanine**
- Trigger anti-tumoral immune responses with **Doxorubicin**






OUR GOAL




Stop tumor recurrence while reducing side effects

Drug cytotoxicity in 2D GBM models

Temozolomide (TMZ)



O⁶-Benzylguanine (O⁶-BG)



IC₅₀ TMZ (72h)
 • T98G: 1871 μM
 • U87: 2198 μM

IC₅₀ O⁶-BG (72h)
 • T98G: 82 μM
 • U87: 86 μM

Can O⁶-BG synergize with TMZ and sensitize cells to this chemotherapy?



?

p* < 0.05; *p* < 0.01; ****p* < 0.001; *****p* < 0.0001 relative to untreated cells – control

Unpublished data, please do not share

O⁶-BG suppresses MGMT expression in GBM 2D models

2D GBM cell monocultures



Long-lasting MGMT inhibition by O⁶-BG reverts chemoresistance to TMZ and sensitizes GBM cells to chemotherapy


**** p < 0.0001 relative to control – untreated cells

Unpublished data, please do not share


TMZ and O⁶-BG synergism in 2D GBM models



T98G



U87



● TMZ
 ■ TMZ + 5 μM O⁶-BG
 ▲ TMZ + 10 μM O⁶-BG
 ◆ TMZ + 25 μM O⁶-BG
 ◆ TMZ + 50 μM O⁶-BG



**TMZ + O⁶-BG defeat
GBM 2D models**



Cytotoxicity (\$\$\$\$)



Synergism (CI<1)




(Chou-Talalay analysis)

^{\$}*p* < 0.05; ^{\$\$}*p* < 0.01; ^{\$\$\$}*p* < 0.001; ^{\$\$\$\$}*p* < 0.0001 relative to TMZ monotherapy; CI – combination index




Unpublished data, please do not share

Drug cytotoxicity in 2D GBM models



Temozolomide (TMZ)




O⁶-Benzylguanine (O⁶-BG)



Doxorubicin (DOX·HCl)



IC₅₀ DOX (72h)
 • T98G: 0.52 μM
 • U87: 0.02 μM




* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$ relative to untreated cells – control

Unpublished data, please do not share


TOX cocktail synergism in 2D GBM models

 TRIPLE drug cocktail → TMZ + O⁶-BG + DOX = TOX

 **T98G**



 **U87**



 **TOX cocktail defeats**
2D GBM models

↑ **Cytotoxicity** (δδ)


↑ **Synergism** (CI<1)

(Chou-Talalay analysis)

****p* < 0.001; *****p* < 0.0001 relative to cells treated with DOX; ^δ*p* < 0.05; ^{δδ}*p* < 0.01 relative to cells without O⁶-BG; CI – combination index

Unpublished data, please do not share

TOX cocktail synergism in 3D GBM spheroid models



Martins et al., JCR, 2023



TOX cocktail destroys 3D tumor and immune GBM spheroids



Cytotoxicity

Synergism (CI<1)
(Chou-Talalay analysis)

T98G




U87



* $p < 0.05$; *** $p < 0.001$; **** $p < 0.0001$ relative to untreated cells – control; £ $p < 0.05$ relative to TMZ monotherapy; Scale bar = 100 μm; CI – combination index



Unpublished data, please do not share

TOX cocktail stimulates calreticulin translocation in 3D GBM spheroid models




Galluzzi et al., Nat Rev Immunol, 2017

T98G




Unpublished data, please do not share

TOX-loaded hydrogel for GBM *in situ* therapy




TOX-LOADED HYDROGEL
made of 25 wt% Pluronic F127
+ 2 wt% Hyaluronic Acid


• Frequency sweep






• Sol-gel transition



• Viscosity




Drug release from hydrogels *in vitro* (aCSF, pH 6.5)



TOX@PF-HA hydrogels are ideal for local GBM therapy


- ✓ Sustained release of TOX
- ✓ Gel-like behavior
- ✓ Thermo-responsiveness
- ✓ Good injectability



Unpublished data, please do not share


Main Conclusions

- ★ **Strong** and **synergistic** anti-tumoral action of **TOX** against 2D and 3D GBM models
- ★ **MGMT** suppression by O⁶-BG is key to **sensitize cells to TMZ**
- ★ **DOX** boosts the **potency** of the combinatorial treatment
- ★ Successful preparation of **TOX-loaded hydrogel** for **localized** GBM treatment



Future steps

- 🔍 Evaluate the therapeutic efficacy of **TOX-loaded hydrogel *in vivo***



Acknowledgements

NTCD Group

Prof. Bruno Sarmento

Prof. Hélder A. Santos

Dr. Cláudia Martins

Dr. Juliana Viegas

Ana Baião

Ana Catarina Pacheco

Ana Margarida Carvalho

Diogo Coelho

Helena Almeida

Sofia Dias

Sónia Siquenique



Prof. Mansoor M. Amiji



i3S Scientific
Platforms



SFRH/BD/06709/2021



PHILADELPHIA, PA
JULY 13-18, 2025

**NEXT-GENERATION
DELIVERY INNOVATIONS**

Novel triple-drug cocktail for glioblastoma exhibits potent synergistic antitumoral effects

Paulo Faria, Mansoor M. Amiji, Hélder A. Santos, Bruno Sarmento

PhD STUDENT
i3S INSTITUTE, UNIVERSITY OF PORTO, PORTUGAL

JULY 18TH 2025